Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311587301> ?p ?o ?g. }
- W4311587301 endingPage "7783" @default.
- W4311587301 startingPage "7772" @default.
- W4311587301 abstract "Abstract Aim To investigate the possible correlation between the development of adverse events (AEs) and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atez/Bev). Methods A total of 286 patients with unresectable HCC treated with Atez/Bev as first‐line systematic therapy were included. Results Regarding treatment‐related AEs, decreased appetite of any grade, proteinuria of any grade, and fatigue of any grade were found with a frequency of ≥20%. Multivariate analysis adjusted for immune‐related liver injury, immune‐related endocrine dysfunction, proteinuria, fatigue, decreased appetite, hypertension, sex, age, Eastern Cooperative Oncology Group performance status, HCC etiology, HCC stage, Child–Pugh score, and α‐fetoprotein showed that hypertension of any grade (hazard ratio [HR], 0.527; 95% confidence interval [CI], 0.326–0.854; p = 0.009) and α‐fetoprotein ≥100 ng/ml (HR, 1.642; 95% CI, 1.111–2.427; p = 0.013) were independently associated with progression‐free survival. Multivariate analysis adjusted for the same AEs showed that fatigue (HR, 2.354; 95% CI, 1.299–4.510; p = 0.010) was independently associated with overall survival. Median progression‐free survival was 6.5 months (95% CI, 5.2–8.1) in patients without hypertension of any grade and 12.6 months (95% CI, 6.7–not available) in patients with hypertension of any grade ( p = 0.035). The overall survival was significantly shorter in patients in whom treatment‐related fatigue of any grade was observed ( p < 0.001). Regarding response rates, the disease control rate of patients who developed treatment‐related hypertension (94.2%) was significantly higher than those who did not (79.1%) ( p = 0.009). Conclusions Treatment‐related hypertension is associated with good outcomes in patients with HCC treated with Atez/Bev." @default.
- W4311587301 created "2022-12-27" @default.
- W4311587301 creator A5002259532 @default.
- W4311587301 creator A5008593372 @default.
- W4311587301 creator A5009103376 @default.
- W4311587301 creator A5013902375 @default.
- W4311587301 creator A5015404124 @default.
- W4311587301 creator A5015534419 @default.
- W4311587301 creator A5017999006 @default.
- W4311587301 creator A5020047441 @default.
- W4311587301 creator A5022551435 @default.
- W4311587301 creator A5023981784 @default.
- W4311587301 creator A5025980433 @default.
- W4311587301 creator A5026964230 @default.
- W4311587301 creator A5028697785 @default.
- W4311587301 creator A5030286729 @default.
- W4311587301 creator A5035134420 @default.
- W4311587301 creator A5035561731 @default.
- W4311587301 creator A5040485741 @default.
- W4311587301 creator A5043762552 @default.
- W4311587301 creator A5047345098 @default.
- W4311587301 creator A5049568375 @default.
- W4311587301 creator A5050706722 @default.
- W4311587301 creator A5051447472 @default.
- W4311587301 creator A5053874442 @default.
- W4311587301 creator A5059536902 @default.
- W4311587301 creator A5061999363 @default.
- W4311587301 creator A5062645991 @default.
- W4311587301 creator A5064418329 @default.
- W4311587301 creator A5064709438 @default.
- W4311587301 creator A5066413780 @default.
- W4311587301 creator A5068214058 @default.
- W4311587301 creator A5072760293 @default.
- W4311587301 creator A5073095975 @default.
- W4311587301 creator A5074947619 @default.
- W4311587301 creator A5080709934 @default.
- W4311587301 creator A5083997418 @default.
- W4311587301 creator A5085648916 @default.
- W4311587301 creator A5085777607 @default.
- W4311587301 creator A5088307695 @default.
- W4311587301 creator A5090570708 @default.
- W4311587301 date "2022-12-14" @default.
- W4311587301 modified "2023-10-16" @default.
- W4311587301 title "Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab" @default.
- W4311587301 cites W1514001646 @default.
- W4311587301 cites W1519496439 @default.
- W4311587301 cites W1902475470 @default.
- W4311587301 cites W1967541992 @default.
- W4311587301 cites W2017558215 @default.
- W4311587301 cites W2021491702 @default.
- W4311587301 cites W2055242813 @default.
- W4311587301 cites W2069126534 @default.
- W4311587301 cites W2075457174 @default.
- W4311587301 cites W2098870242 @default.
- W4311587301 cites W2113652101 @default.
- W4311587301 cites W2113832885 @default.
- W4311587301 cites W2121960517 @default.
- W4311587301 cites W2140642422 @default.
- W4311587301 cites W2147172608 @default.
- W4311587301 cites W2163403599 @default.
- W4311587301 cites W2163486683 @default.
- W4311587301 cites W2171715330 @default.
- W4311587301 cites W2342654843 @default.
- W4311587301 cites W2584632358 @default.
- W4311587301 cites W2591717879 @default.
- W4311587301 cites W2794457872 @default.
- W4311587301 cites W2903486314 @default.
- W4311587301 cites W2912725678 @default.
- W4311587301 cites W2942467666 @default.
- W4311587301 cites W2945730831 @default.
- W4311587301 cites W2982497080 @default.
- W4311587301 cites W2997720498 @default.
- W4311587301 cites W3016705084 @default.
- W4311587301 cites W3025022288 @default.
- W4311587301 cites W3026099517 @default.
- W4311587301 cites W3042091422 @default.
- W4311587301 cites W3128646645 @default.
- W4311587301 cites W3131552574 @default.
- W4311587301 cites W3170378498 @default.
- W4311587301 cites W3178394495 @default.
- W4311587301 cites W3213789516 @default.
- W4311587301 cites W4210547611 @default.
- W4311587301 cites W4224226040 @default.
- W4311587301 cites W4225310390 @default.
- W4311587301 cites W4281695324 @default.
- W4311587301 cites W4281762900 @default.
- W4311587301 cites W4283395775 @default.
- W4311587301 cites W4311587301 @default.
- W4311587301 doi "https://doi.org/10.1002/cam4.5535" @default.
- W4311587301 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36518086" @default.
- W4311587301 hasPublicationYear "2022" @default.
- W4311587301 type Work @default.
- W4311587301 citedByCount "6" @default.
- W4311587301 countsByYear W43115873012022 @default.
- W4311587301 countsByYear W43115873012023 @default.
- W4311587301 crossrefType "journal-article" @default.
- W4311587301 hasAuthorship W4311587301A5002259532 @default.
- W4311587301 hasAuthorship W4311587301A5008593372 @default.